Alpha 2.0
Login Register
» Authors » Andreas Limacher

Andreas Limacher

Explore the profile of Andreas Limacher including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 118
Citations 1390
Followers 0
Related Specialties
General Medicine
Science
Hematology
Top 10 Co-Authors
Drahomir Aujesky
Marie Mean
Nicolas Rodondi
Marc Righini
Odile Stalder
Peter Juni
Nils Kucher
Tobias Tritschler
Markus Aschwanden
Anne Angelillo-Scherrer
Published In
PLoS One
BMJ Open
Thromb Res
Am J Med
J Thromb Haemost
Affiliations
Soon will be listed here.
Recent Articles
1.
Epidemiology and risk factors of expatriates returning to Switzerland colonized at the intestinal level with multidrug-resistant Enterobacterales
Campos-Madueno E, Aldeia C, Roumet M, Limacher A, Sendi P, Endimiani A
Eur J Clin Microbiol Infect Dis . 2025 Feb; PMID: 39953366
Living in high-endemic regions increases the risk of intestinal colonization by multidrug-resistant Enterobacterales (MDR-Ent). This study investigated Swiss expatriates residing abroad (≥ 3 months) to assess their colonization status upon...
2.
Accuracy of screening tests for cervical precancer in women living with HIV in low-resource settings: a paired prospective study in Lusaka, Zambia
Taghavi K, Moono M, Mwanahamuntu M, Roumet M, Limacher A, Kapesa H, et al.
BMJ Oncol . 2025 Jan; 3(1):e000111. PMID: 39886160
Objective: This study aimed to provide evidence to improve cervical screening for women living with HIV (WLHIV). We assessed the accuracy of screening tests that can be used in low-resource...
3.
Booster-free anti-retroviral therapy for persons living with HIV and multidrug resistance (B-Free): protocol for a multicentre, multistage, randomised, controlled, non-inferiority trial
Ballif M, Braun D, Calmy A, Bernasconi E, Cavassini M, Tissot F, et al.
BMJ Open . 2024 Nov; 14(11):e094912. PMID: 39578038
Introduction: Anti-retroviral therapy (ART) simplification strategies are needed for treatment-experienced people with HIV (PWH) and multidrug-resistant viruses. These individuals are commonly treated with boosted ART regimens and are thereby at...
4.
Effect of goal-directed mobilisation versus standard care on physical functioning among medical inpatients: the GoMob-in randomised, controlled trial
Liechti F, Heinzmann J, Schmutz N, Rossen M, Rossel J, Limacher A, et al.
BMJ Open . 2024 Nov; 14(11):e086921. PMID: 39542489
Objective: To assess the effect of goal-directed mobilisation (GDM) on physical functioning in medical inpatients. Design: Randomised, controlled, single-centre, parallel, superiority trial with a 3-month follow-up and blinded outcome assessment....
5.
Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV Trial
Marinosci A, Sculier D, Wandeler G, Yerly S, Stoeckle M, Bernasconi E, et al.
Open Forum Infect Dis . 2024 Nov; 11(11):ofae618. PMID: 39507885
The SIMPL'HIV study investigated whether switching to dolutegravir (DTG) + emtricitabine (FTC) was noninferior to continuing combined antiretroviral therapy for maintaining HIV-1 suppression at 144 weeks. The study demonstrated that...
6.
Apixaban dosing in hemodialysis - can drug level monitoring mitigate controversies?
Schietzel S, Limacher A, Moor M, Czerlau C, Huynh-Do U, Vogt B, et al.
BMC Nephrol . 2024 Oct; 25(1):338. PMID: 39385105
Background: Inconsistent study results and contradictory recommendations from health authorities regarding the use of apixaban in patients on hemodialysis have generated considerable uncertainty among clinicians, making investigations of appropriate dosing...
7.
Baseline platelet count and long-term clinical outcomes in patients with acute venous thromboembolism: a prospective cohort study
Stuby J, Stalder O, Limacher A, Righini M, Rodondi N, Tritschler T, et al.
Ann Hematol . 2024 Sep; 103(11):4721-4729. PMID: 39249495
An abnormal platelet count (PC) is common in acute venous thromboembolism (VTE) but its relationship with clinical outcomes remains ill-defined. We aimed to explore the association between baseline PC and...
8.
Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy: the SIMPL'HIV open-label, factorial randomised controlled trial
Marinosci A, Sculier D, Wandeler G, Yerly S, Stoeckle M, Bernasconi E, et al.
Swiss Med Wkly . 2024 May; 154:3762. PMID: 38754068
Background: Clinical and laboratory monitoring of patients on antiretroviral therapy is an integral part of HIV care and determines whether treatment needs enhanced adherence or modification of the drug regimen....
9.
Acceptance, Satisfaction, and Preference With Telemedicine During the COVID-19 Pandemic in 2021-2022: Survey Among Patients With Chronic Pain
Harnik M, Scheidegger A, Blattler L, Nemecek Z, Sauter T, Limacher A, et al.
JMIR Form Res . 2024 Apr; 8:e53154. PMID: 38684086
Background: The COVID-19 pandemic has forced many health care providers to make changes in their treatment, with telemedicine being expanded on a large scale. An earlier study investigated the acceptance...
10.
Histological Phenotyping in Eosinophilic Esophagitis: Localized Proximal Disease Is Infrequent but Associated with Less Severe Disease and Better Disease Outcome
Heil A, Kuehlewindt T, Godat A, Simon H, Simon D, Schreiner P, et al.
Int Arch Allergy Immunol . 2023 Oct; 185(1):63-72. PMID: 37866349
Introduction: It is still unknown whether eosinophilic esophagitis (EoE) patients with localized disease are different from those with extended disease. Methods: We evaluated prospectively included patients in the Swiss EoE...